O-113 Clinical evaluation of gefitinib (Iressa, ZD1839) in combination with rofecoxib in
cisplatin pre-treated relapsed non-small cell lung cancer × Close The Infona portal uses …

Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-
inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor …

Lung cancer is one of the most common causes of cancer death worldwide. Although recent
advances in chemotherapy and radiation therapy have yielded modest improvements in …

7025 Background: Increased expression of eicosanoids have been associated with adverse
prognosis. Specific inhibitors of key enzymes of two eicosanoid pathways, COX-2 …

Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic
states such as inflammatory processes and cancer. The enzyme is often overexpressed in …

Background COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway
inhibitors, such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in …

7312 Background: Constitutive overexpression of COX-2 is common in NSCLC, and this
could be linked to tumor progression. Some preclinical studies suggest that a selective COX …

Purpose This phase I study was conducted to determine the safety, tolerability and maximum
tolerated dose of the combination of celecoxib, a selective cyclooxygenase-2 inhibitor, with …

Despite a large number of studies indicating that celecoxib plays an important role in the
prevention and treatment of tumors, the detailed molecular mechanisms are not well …

Our study investigates the effect of a highly selective cyclooxygenase‐2 (COX‐2) inhibitor,
celecoxib, on the cytotoxicity of docetaxel in nude mice bearing A549 tumor xenografts and …